Global Visceral Pain Market Size Projected to Reach $18.58 Billion During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Visceral Pain Market Expected To Expand Between 2025 And 2029?

The visceral pain market size has shown substantial growth in recent years. It is projected to expand from $13.84 billion in 2024 to $14.82 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. The expansion observed historically can be attributed to an aging population, an increased incidence of chronic diseases, advancements in medical research, the expansion of healthcare infrastructure, and rising awareness and diagnosis rates.

The visceral pain market is projected to experience substantial expansion over the upcoming years, with its valuation reaching “$18.58 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.8%. This anticipated increase is primarily driven by advancements in pain management technology, a rising preference for non-invasive treatments, the emergence of new markets alongside untapped prospects, customized medicine strategies, and the incorporation of digital health solutions. Key developments expected throughout the forecast period involve a move towards comprehensive multimodal pain management, a greater focus on alternative treatments, the emergence of therapies targeting specific pain types, an expanding role for telemedicine in managing pain, and the application of artificial intelligence in evaluating pain.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13950&type=smp

Which Industry Drivers Are Expected To Accelerate The Visceral Pain Market From 2025 To 2029?

The increasing demand for pain relievers is anticipated to propel the expansion of the visceral pain market moving forward. These medications function by reducing or obstructing the perception of pain signals in the brain to alleviate discomfort. They assist in managing visceral pain by targeting the nervous system and modulating signals originating from internal organs. For instance, in April 2024, data published in the New England Journal of Medicine, a UK-based weekly medical journal, showed that over 53,600 clinicians were prescribing buprenorphine by December 2023. This figure represents an increase of 11,500 prescribers compared to December 2022. Consequently, the escalating demand for analgesics is a significant driver for the growth of the visceral pain market.

What Are The Major Segments Identified In The Visceral Pain Market?

The visceral painmarket covered in this report is segmented –

1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes

2) By Indications: Interstitial Cystitis; Crohn’s; Irritable Bowel; Chronic Prostatitis; Other Indications

3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors; Non-Selective NSAIDs

3) By Other Drug Classes: Opioids; Tricyclic Antidepressants (TCAs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

What Are The Latest Industry Trends Transforming The Visceral Pain Market?

Leading companies operating within the visceral pain market are actively developing innovative products, such as the NHE3 Inhibitor, to offer reliable solutions to customers. NHE3 inhibitors represent a class of medications designed to function by suppressing the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For instance, in April 2022, Ardelyx, a US-based biopharmaceutical company, introduced an NHE3 Inhibitor drug called IBSRELA. IBSRELA stands as a pioneering treatment for adults diagnosed with irritable bowel syndrome with constipation (IBS-C), and its mechanism involves inhibiting the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Animal studies have indicated its ability to reduce abdominal pain by diminishing visceral hypersensitivity and intestinal permeability.

Which Global Market Leaders Are Shaping The Future Of The Visceral Pain Sector?

Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

Which Region Currently Holds The Largest Share Of The Visceral Pain Market?

North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Visceral Pain Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13950&type=smp

Browse Through More Reports Similar to the Global Visceral Pain Market 2025, By The Business Research Company

Neuropathic Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Joint Pain Injections Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

Veterinary Pain Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-pain-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795